Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 2/20 | 0.62 |
| ▸ | CTSS | P25774 | 5/20 | 0.58 |
| ▸ | CTSL | P07711 | 4/20 | 0.58 |
| ▸ | CTSB | P07858 | 3/20 | 0.58 |
| ▸ | CTSK | P43235 | 4/20 | 0.52 |
| ▸ | MME | P08473 | 1/20 | 0.51 |
| ▸ | APC | P25054 | 1/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.50 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27753302 | 1.00 | ECE1 (0.62) | ECE1CTSSCTSLCTSBCTSK | |
| SCHEMBL27732937 | 0.88 | CTSB (0.55) | ECE1CTSSCTSLCTSBCTSK | |
| SCHEMBL1841852 | 0.88 | CTSB (0.55) | ECE1CTSSCTSLCTSBCTSK | |
| SCHEMBL5963300 | 0.85 | CTSB (0.57) | ECE1CTSSCTSLCTSBCTSK | |
| SCHEMBL16463321 | 0.84 | ATM (0.54) | ECE1CTSSCTSLCTSBCTSK | |
| SCHEMBL17106905 | 0.84 | ATM (0.54) | ECE1CTSSCTSLCTSBCTSK | |
| SCHEMBL1849406 | 0.83 | CTSS (0.59) | ECE1CTSSCTSLCTSBCTSK | |
| SCHEMBL1852485 | 0.82 | CTSS (0.58) | ECE1CTSSCTSLCTSBCTSK | |
| SCHEMBL27964688 | 0.82 | CTSS (0.58) | ECE1CTSSCTSLCTSBCTSK | |
| SCHEMBL1702159 | 0.81 | ECE1 (0.65) | ECE1CTSSCTSLCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957205-B2 | Cycloalkane carboxamide derivatives and production process of same | SEIKAGAKU CORPORATION (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8481725-B2 | Cycloalkylcarbonylamino acid derivative and process for producing the same | SEIKAGAKU CORPORATION (JP) | 2013-07-09 | — | — | US | disclosed |
| EP-1972636-B1 | CYCLOALKYLCARBONYLAMINO ACID DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | SEIKAGAKU KOGYO CO LTD (JP) | 2011-05-25 | — | — | EP | disclosed |
| US-20090156805-A1 | Cycloalkane Carboxamide Derivatives and Production Process of Same | SEIKAGAKU CORPORATION (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090111983-A1 | Cycloalkylcarbonylamino Acid Derivative and Process For Producing The Same | SEIKAGAKU CORPORATION (JP) | 2009-04-30 | — | — | US | disclosed |
| CN-101370773-A | Cycloalkanecarboxamide derivative and method for producing same | SEIKAGAKU KOGYO CO LTD (JP) | 2009-02-18 | — | — | CN | disclosed |
| EP-1972636-A1 | CYCLOALKYLCARBONYLAMINO ACID DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | SEIKAGAKU CORPORATION (JP) | 2008-09-24 | — | — | EP | disclosed |
| EP-1972615-A1 | CYCLOALKANECARBOXAMIDE DERIVATIVE AND METHOD FOR PRODUCING SAME | SEIKAGAKU CORPORATION (JP) | 2008-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156805-A1 | Cycloalkane Carboxamide Derivatives and Production Process of Same | CTSK, CTSS, CTSB | ECE1 358/4885CTSS 2/4885CTSL 13/4885 |
| US-20090111983-A1 | Cycloalkylcarbonylamino Acid Derivative and Process For Producing The Same | CTSK, CTSS, CTSV | ECE1 613/4885CTSS 2/4885CTSL 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.